News & Updates

Combination a better bet than monotherapy in mixed dyslipidemia

23 Sep 2020 by

The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.

Combination a better bet than monotherapy in mixed dyslipidemia

23 Sep 2020

Brensocatib tackles exacerbations in bronchiectasis

22 Sep 2020 by

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Brensocatib tackles exacerbations in bronchiectasis

22 Sep 2020

Masitinib demonstrates potential for severe asthma

22 Sep 2020 by

The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.

Masitinib demonstrates potential for severe asthma

22 Sep 2020

Solifenacin improves urinary symptoms but worsens constipation in MS patients with OAB

22 Sep 2020

In the treatment of multiple sclerosis (MS) patients with overactive bladder (OAB), mirabegron and solifenacin yield similar response rates, with the latter producing a greater decrease in urinary symptom severity but exerting a less favourable effect on constipation, a study has found.

Solifenacin improves urinary symptoms but worsens constipation in MS patients with OAB

22 Sep 2020

Daily albumin infusion fails to reduce infection, renal dysfunction in decompensated cirrhosis

21 Sep 2020 by

Daily albumin infusion to achieve serum albumin levels of ≥30 g/L did not reduce the risk of infection, renal dysfunction, or mortality in individuals with acute decompensated cirrhosis, according to results of the ATTIRE* study presented at ILC 2020.

Daily albumin infusion fails to reduce infection, renal dysfunction in decompensated cirrhosis

21 Sep 2020

How to control asthma well: Experts’ perspectives

21 Sep 2020 by

Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.

How to control asthma well: Experts’ perspectives

21 Sep 2020

Antireflux drug not as beneficial in idiopathic pulmonary fibrosis treatment

21 Sep 2020

While gastroesophageal reflux disease is a common comorbidity in idiopathic pulmonary fibrosis (IPF), treatment with a proton pump inhibitor does not appear to have any bearing on mortality and hospitalization outcomes among IPF patients, according to real-world data.

Antireflux drug not as beneficial in idiopathic pulmonary fibrosis treatment

21 Sep 2020

Experimental drug shows therapeutic potential in acute vulvovaginal candidiasis

19 Sep 2020

The oral antifungal drug VT-1161 (oteseconazole) is safe and effective in the treatment of women with acute vulvovaginal candidiasis (VVC), according to the results of a phase II study.

Experimental drug shows therapeutic potential in acute vulvovaginal candidiasis

19 Sep 2020

Cranberry juice a potential treatment for H pylori infection?

19 Sep 2020 by

Consuming cranberry juice twice daily for 8 weeks can help suppress Helicobacter (H.) pylori infection among Chinese adults, suggests a randomized study — thus opening the door to using cranberry juice as a complementary approach to H. pylori management.

Cranberry juice a potential treatment for H pylori infection?

19 Sep 2020

First-line triple combo therapy shows potential in PAH

18 Sep 2020 by

Adding selexipag to the double combination therapy of macitentan and tadalafil (triple combination) improved multiple outcomes in patients newly diagnosed with pulmonary arterial hypertension (PAH), results of the phase IIIb TRITON* trial showed.

First-line triple combo therapy shows potential in PAH

18 Sep 2020

News & Updates

Filter by Specialty:

Specialty:

Combination a better bet than monotherapy in mixed dyslipidemia

Combination a better bet than monotherapy in mixed dyslipidemia

Brensocatib tackles exacerbations in bronchiectasis

Brensocatib tackles exacerbations in bronchiectasis

Masitinib demonstrates potential for severe asthma

Masitinib demonstrates potential for severe asthma

Solifenacin improves urinary symptoms but worsens constipation in MS patients with OAB

Solifenacin improves urinary symptoms but worsens constipation in MS patients with OAB

Daily albumin infusion fails to reduce infection, renal dysfunction in decompensated cirrhosis

Daily albumin infusion fails to reduce infection, renal dysfunction in decompensated cirrhosis

How to control asthma well: Experts’ perspectives

How to control asthma well: Experts’ perspectives

Antireflux drug not as beneficial in idiopathic pulmonary fibrosis treatment

Antireflux drug not as beneficial in idiopathic pulmonary fibrosis treatment

Experimental drug shows therapeutic potential in acute vulvovaginal candidiasis

Experimental drug shows therapeutic potential in acute vulvovaginal candidiasis

Cranberry juice a potential treatment for H pylori infection?

Cranberry juice a potential treatment for H pylori infection?

First-line triple combo therapy shows potential in PAH

First-line triple combo therapy shows potential in PAH